AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25257148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine (quetiapine XR; 150 or 300 mg/day)
Number of subjects: 919
Study 25257148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study 23713578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment to lower blood pressure (target systolic level <140 mm Hg within 1 hour)
Number of subjects: 2839
Study 23713578 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target systolic level <180 mm Hg)
Number of subjects: 2839
Study 23713578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment to lower blood pressure
Number of subjects: 2839
Study 23713578 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment
Number of subjects: 2839
Study 21665546 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant LH (rLH) administration
Number of subjects: 475
Study 21665546 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-follicular-phase LH concentration
Number of subjects: 475
Study 21665546 — intervention group
Group type: COMPARATOR
Intervention: rLH administration
Number of subjects: 475
Study 18298240 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 201
Study 18298240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 201
Study 16239314 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds co-incubation (group A)
Number of subjects: 81
Study 16239314 — intervention group
Group type: COMPARATOR
Intervention: 90 minutes co-incubation (group B)
Number of subjects: 81
Study 14979510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest pressurisation rate
Number of subjects: 15
Study 14979510 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pressurisation rates
Number of subjects: 15
Study 14979510 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 15
Study 11172114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollerball endometrial ablation
Number of subjects: 275
Study 11172114 — intervention group
Group type: COMPARATOR
Intervention: Uterine balloon therapy
Number of subjects: 275
Study 9292174 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal surgery
Number of subjects: 31
Study 8305662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 2 (2 micrograms/kg/min)
Number of subjects: 35
Study 8305662 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 35
Study 8305662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 1 (1 microgram/kg/min)
Number of subjects: 35
Study 3521269 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam plus piperacillin
Number of subjects: 302
Study 3521269 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam plus amikacin
Number of subjects: 302
Study 30322090 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack replacement (n = 24)
Number of subjects: 46
Study 30322090 — intervention group
Group type: COMPARATOR
Intervention: Snack reduction (n = 22)
Number of subjects: 46
Study 27072496 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded glucose infusion (GGI)
Number of subjects: 0
Study 27072496 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological effects
Number of subjects: 0
Study 24735024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy + standard palliative care (SPC)
Number of subjects: 80
Study 24735024 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care (SPC) alone
Number of subjects: 80
Study 22020992 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 61
Study 22020992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d-methamphetamine
Number of subjects: 61
Study 22020992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20516483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo) with contrast
Number of subjects: 60
Study 20516483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo)
Number of subjects: 60
Study 20516483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo) and DE-cMR
Number of subjects: 60
Study 18172188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT) with goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with external-beam radiotherapy (EBRT)
Number of subjects: 456
Study 18172188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT) with EBRT
Number of subjects: 456
Study 18172188 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiotherapy (EBRT) alone
Number of subjects: 456
Study 15567450 — intervention group
Group type: EXPERIMENTAL
Intervention: Armagnac (30 ml/day for 2 weeks)
Number of subjects: 20
Study 15567450 — intervention group
Group type: COMPARATOR
Intervention: Vodka (same alcoholic strength, 30 ml/day for 2 weeks)
Number of subjects: 20
Study 15567450 — intervention group
Group type: EXPERIMENTAL
Intervention: Armagnac
Number of subjects: 20
Study 15567450 — intervention group
Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 20
Study 15567450 — intervention group
Group type: EXPERIMENTAL
Intervention: Armagnac and Vodka
Number of subjects: 20
Study 14608565 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver (PRM)
Number of subjects: 40
Study 14608565 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (Control)
Number of subjects: 40
Study 11706098 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1000 mg PO twice a day for 6 weeks)
Number of subjects: 899
Study 11706098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 899
Study 9501484 — intervention group
Group type: EXPERIMENTAL
Intervention: Underreporting group with brief information about validity scales
Number of subjects: 0
Study 9501484 — intervention group
Group type: EXPERIMENTAL
Intervention: Underreporting group with no information about validity scales
Number of subjects: 0
Study 9501484 — intervention group
Group type: COMPARATOR
Intervention: Standard control group (no underreporting instructions)
Number of subjects: 0
Study 9501484 — intervention group
Group type: COMPARATOR
Intervention: Demographically matched group from the general population
Number of subjects: 0
Study 7961535 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 60 mg
Number of subjects: 274
Study 7961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg daily)
Number of subjects: 274
Study 7961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (various doses: 20, 40, and 60 mg)
Number of subjects: 274
Study 7961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (in responder extension)
Number of subjects: 274
Study 7961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (open-label extension)
Number of subjects: 274
Study 3567046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 3567046 — intervention group
Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 0
Study 3567046 — intervention group
Group type: COMPARATOR
Intervention: NDMC
Number of subjects: 0
Study 31877362 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to recorded classical music for at least 30 minutes per day for 3 months.
Number of subjects: 159
Study 31877362 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 159
Study 28866091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake measured by 24-hour urine collections (mean intake 3,903 mg/day, standard deviation 1037 mg/day)
Number of subjects: 119
Study 26936446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-pressure profile training
Number of subjects: 14
Study 26936446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-pressure strength and accuracy training
Number of subjects: 14
Study 26936446 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study 24635691 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-Prep (Peer-Mentored Prep)
Number of subjects: 82
Study 24635691 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control arm
Number of subjects: 82
Study 22412088 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial infusion of NO synthase inhibitor (N(G)-monomethyl-l-arginine [L-NMMA])
Number of subjects: 58
Study 22412088 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial infusion of cytochrome P450 epoxygenase inhibitor (fluconazole)
Number of subjects: 58
Study 22412088 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-NMMA and fluconazole
Number of subjects: 58
Study 22412088 — intervention group
Group type: COMPARATOR
Intervention: Heating-induced flow-mediated dilatation
Number of subjects: 58
Study 22412088 — intervention group
Group type: COMPARATOR
Intervention: Local plasma epoxyeicosatrienoic acids
Number of subjects: 58
Study 22412088 — intervention group
Group type: COMPARATOR
Intervention: Plasma nitrite
Number of subjects: 58
Study 22412088 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive oxygen species
Number of subjects: 58
Study 22412088 — intervention group
Group type: COMPARATOR
Intervention: Plasma endothelin-1
Number of subjects: 58
Study 20079863 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 147
Study 20079863 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 147
Study 20079863 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg/day orally for 6 months
Number of subjects: 147
Study 20079863 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 147
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: EcoScreen
Number of subjects: 12
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Tube at ‐20 degrees C
Number of subjects: 12
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Tube at ‐70 degrees C
Number of subjects: 12
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Tube and Anacon
Number of subjects: 12
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene B(4)
Number of subjects: 12
Study 18249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteinyl‐leukotriene
Number of subjects: 12
Study 16816277 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 306
Study 16816277 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 306
Study 12504694 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass resolution perimetry (HRP)
Number of subjects: 82
Study 12504694 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 82
Study 12504694 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology (FDT)
Number of subjects: 82
Study 11078227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (140 microg/kg/min for 6 minutes) and Heparin (10,000 U bolus)
Number of subjects: 21
Study 11078227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8842597 — intervention group
Group type: EXPERIMENTAL
Intervention: DH Pressure Relief Walkers (DH)
Number of subjects: 35
Study 8842597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Contact Casts (TCCs)
Number of subjects: 35
Study 8842597 — intervention group
Group type: COMPARATOR
Intervention: Commercially available therapeutic shoes and removable walking casts
Number of subjects: 35
Study 1299455 — intervention group
Group type: EXPERIMENTAL
Intervention: COOP Chart illustrations
Number of subjects: 177
Study 1299455 — intervention group
Group type: COMPARATOR
Intervention: No illustrations
Number of subjects: 177
Study 30883671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine + 100 mcg of fentanyl
Number of subjects: 60
Study 30883671 — intervention group
Group type: COMPARATOR
Intervention: 0.125% levobupivacaine + 100 mcg of fentanyl
Number of subjects: 60
Study 27979754 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV) model
Number of subjects: 154
Study 27979754 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 154
Study 26112283 — intervention group
Group type: EXPERIMENTAL
Intervention: Large positive or negative intrathoracic pressures
Number of subjects: 0
Study 26112283 — intervention group
Group type: COMPARATOR
Intervention: Modest intrathoracic pressures or large lung volumes
Number of subjects: 0
Study 24671538 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS) 250 mg
Number of subjects: 61
Study 24671538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21515561 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC) for 1 min
Number of subjects: 51
Study 21515561 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC) for 3 min
Number of subjects: 51
Study 21515561 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (ELC for 1 min and 3 min)
Number of subjects: 51
Study 21515561 — intervention group
Group type: COMPARATOR
Intervention: Control (no eyelid closure)
Number of subjects: 51
Study 20402328 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 436
Study 20402328 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 436
Study 17160498 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA/PRP combination
Number of subjects: 28
Study 17160498 — intervention group
Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 28
Study 15684017 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with interstitial chemotherapy (carmustine) after microsurgery
Number of subjects: 28
Study 15684017 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 28
Study 11991437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day for 2 years
Number of subjects: 0
Study 11991437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 0
Study 9489270 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically Supported Treatments (ESTs)
Number of subjects: 0
Study 9489270 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized treatment
Number of subjects: 0
Study 9489270 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientist-practitioner model
Number of subjects: 0
Study 7611583 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine intraarticularly diluted in 10 ml saline
Number of subjects: 59
Study 7611583 — intervention group
Group type: COMPARATOR
Intervention: 1 mg morphine intravenously diluted in 10 ml saline (control)
Number of subjects: 59
Study 2195225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon monofilament 10-0 suture
Number of subjects: 26
Study 2195225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene 10-0 suture
Number of subjects: 26
Study 76170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 31
Study 76170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide in large doses
Number of subjects: 31
Study 76170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 31
Study 30845977 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive approach (antipyretic interventions only at ≥ 39.5 °C)
Number of subjects: 100
Study 30845977 — intervention group
Group type: COMPARATOR
Intervention: Restrictive approach (antipyretic interventions at ≥ 37.5 °C)
Number of subjects: 100
Study 30845977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 27736795 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of split-dose 4L polyethylene-glycol (group A)
Number of subjects: 143
Study 27736795 — intervention group
Group type: COMPARATOR
Intervention: Split-dose sodium picosulphate/magnesium citrate (group B)
Number of subjects: 143
Study 27736795 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized preparation based on a 3-item questionnaire (group C)
Number of subjects: 143
Study 27736795 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose 4L polyethylene-glycol
Number of subjects: 143
Study 25647451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 16
Study 25647451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23228248 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal reduction (OR group)
Number of subjects: 54
Study 23228248 — intervention group
Group type: COMPARATOR
Intervention: No occlusal reduction (NOR group)
Number of subjects: 54
Study 22232849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg film-coated tablet (FCT)
Number of subjects: 0
Study 22232849 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg chewable tablet (CT)
Number of subjects: 0
Study 19188334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐1.4 microg/kg per hour)
Number of subjects: 375
Study 19188334 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.02‐0.1 mg/kg per hour)
Number of subjects: 375
Study 19188334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 375
Study 19188334 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 375
Study 16887430 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 70
Study 16887430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15312472 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (IPM)
Number of subjects: 13
Study 15312472 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone (CPZ)
Number of subjects: 13
Study 10914936 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations (mutation+)
Number of subjects: 200
Study 10914936 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 200
Study 10914936 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable karyotypes
Number of subjects: 200
Study 10914936 — intervention group
Group type: COMPARATOR
Intervention: p53 accumulation (mutation‐/accumulation+)
Number of subjects: 200
Study 10914936 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 accumulation (mutation+)
Number of subjects: 200
Study 10914936 — intervention group
Group type: COMPARATOR
Intervention: p53 accumulation
Number of subjects: 200
Study 9314423 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion at a rate of 3.3 pmol x kg(‐1) x min(‐1) over 4 hours
Number of subjects: 8
Study 8359274 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 13
Study 3534509 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 229
Study 3534509 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (compliers)
Number of subjects: 229
Study 3534509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 31791663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo)
Number of subjects: 505
Study 31791663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo)
Number of subjects: 505
Study 31791663 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection (IAI) alone
Number of subjects: 505
Study 31791663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular inflammation incidence
Number of subjects: 505
Study 31791663 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events incidence
Number of subjects: 505
Study 29718421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 207
Study 29718421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 207
Study 29718421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 207
Study 29718421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 26294293 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1200 mg/day) and Vitamin D (800 IU/day)
Number of subjects: 40
Study 26294293 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg/day), Vitamin D (800 IU/day), and Strontium ranelate (2 g daily)
Number of subjects: 40
Study 26200465 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.24 µg·kg·min)
Number of subjects: 10
Study 26200465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26200465 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 10
Study 24135387 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) defined as 100-125 mg/dL
Number of subjects: 1690
Study 24135387 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated HbA1c defined as 5.7-6.4%
Number of subjects: 1690
Study 24135387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFG and elevated HbA1c
Number of subjects: 1690
Study 24135387 — intervention group
Group type: COMPARATOR
Intervention: Addition of elevated HbA1c to the model with IFG
Number of subjects: 1690
Study 21107327 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg per day, titrated to 100 mg per day for 13 months
Number of subjects: 288
Study 21107327 — intervention group
Group type: COMPARATOR
Intervention: ramipril 5 mg per day, titrated to 10 mg per day for 13 months
Number of subjects: 288
Study 19099689 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Kawasaki disease (KD)
Number of subjects: 56
Study 19099689 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive Kawasaki disease (KD)
Number of subjects: 56
Study 19099689 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-infectious diseases)
Number of subjects: 56
Study 19099689 — intervention group
Group type: COMPARATOR
Intervention: Control group (febrile patients)
Number of subjects: 56